Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q1

3151.TEDINET S100RLIV
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥144.5bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥143.9bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.2bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥849m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.5bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.2bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.4bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥917m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥640m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥945m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥675m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥305.7bnat 2023-06-30Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥314.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥203.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥101.4bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥21.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥17.812023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥12.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio33.0%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥648m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥90m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥15m
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2023-04-01 → 2023-06-30¥138.7bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2023-04-01 → 2023-06-30¥135.9bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2023-04-01 → 2023-06-30¥1.1bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥4.7bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥4.7bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥87m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥99m
—segment totalrevenue2023-04-01 → 2023-06-30¥146.1bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥143.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥2.8bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥148.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥144.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥69m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2022-04-01 → 2022-06-30¥138.4bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2022-04-01 → 2022-06-30¥135.6bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2022-04-01 → 2022-06-30¥783m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥14m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥121m
—segment totalrevenue2022-04-01 → 2022-06-30¥145.5bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥142.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥919m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥147.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥143.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥850m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 362
ItemContextValueUnit
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E22440-000MedicineWholesaleReportableSegmentMember2769000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E22440-000PharmacyBusinessReportableSegmentMember3000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember0JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember2772000000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember648000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember3421000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-3421000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E22440-000MedicineWholesaleReportableSegmentMember138691000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E22440-000PharmacyBusinessReportableSegmentMember4657000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember2783000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember146132000000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1830000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember147963000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-3421000000JPY
Net salesCurrentYTDDuration144542000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E22440-000MedicineWholesaleReportableSegmentMember1054000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E22440-000PharmacyBusinessReportableSegmentMember87000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember99000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember1242000000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-90000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1151000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember15000000JPY
Operating incomeCurrentYTDDuration1167000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-08-09
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第15期第１四半期(自 2023年４月１日 至 2023年６月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス
Company name in english cover pageFilingDateInstantVITAL KSK HOLDINGS, INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　村　井　泰　介
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)(03)5787－8550(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員経営企画部長　　高　橋　喜　春
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)(03)5787－8550(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員経営企画部長　　高　橋　喜　春
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE22440
Fund codeFilingDateInstant－
Security codeFilingDateInstant31510
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス
Filer name in englishFilingDateInstantVITAL KSK HOLDINGS,INC.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass